CPT Coding Guidance for VVT Medical’s ScleroSafe Procedure Reviewed by AVF

September 3, 2024—VVT Medical announced that the American Venous Forum (AVF) has provided an official opinion letter regarding CPT coding guidance for the ScleroSafe percutaneous endovenous ablation procedure. VVT is a medical device company headquartered in Israel.

According to VVT Medical, the AVF Health Policy Committee convened on August 13, 2024, to review and discuss the company’s ScleroSafe device. The committee confirmed that the procedures performed using the ScleroSafe device are accurately described by the current CPT codes 36473 and 36474, which cover endovenous ablation therapy of incompetent vein extremities, inclusive of all imaging guidance and monitoring.

The AVF opinion letter is available on VVT Medical’s website here.

The company stated that the procedure, which combines mechanical collapse and chemical ablation to treat incompetent varicose veins, is now well supported by the existing CPT codes 36473 and 36474.

As outlined in VVT Medical’s press release, the CPT code descriptors are:

• 36473, “Endovenous ablation therapy of incompetent vein extremity inclusive of all imaging guidance and monitoring percutaneous mechanochemical; first vein treated.”
• 36474, “Endovenous ablation therapy of incompetent vein extremity inclusive of all imaging guidance and monitoring percutaneous mechanochemical; subsequent vein(s) treated in a single extremity each through separate access sites.”

VVT Medical advised that the ScleroSafe device utilizes mechanical disruption and abrasion of the venous intima, combined with the infusion of a physician-specified sclerosant using the ScleroSafe dual-procedure syringe/catheter system to provide a comprehensive solution for treating varicose veins.

In 2023, the company announced that ScleroSafe received FDA 510(k) clearance for nonthermal, nontumescent treatment and management of varicosities in superficial veins. The predicate device was ClariVein (Merit Medical), noted VVT Medical.

In January 2024, VVT Medical announced a strategic distribution agreement with Methapharm Inc. for the marketing of the ScleroSafe platform for varicose veins treatment in the United States.